Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | EIF4E | P06730 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119875 | 1.00 | PROKR2 (0.57) | PROKR2MAPK1ANO1KDM4EALDH1A1 | |
| SCHEMBL564805 | 0.86 | PROKR2 (0.72) | PROKR2 | |
| SCHEMBL13284400 | 0.86 | PROKR2 (0.62) | PROKR2 | |
| SCHEMBL565577 | 0.86 | PROKR2 (0.72) | PROKR2 | |
| SCHEMBL565626 | 0.86 | PROKR2 (0.72) | PROKR2 | |
| SCHEMBL13284338 | 0.85 | PROKR2 (0.61) | PROKR2ADORA2AADORA1 | |
| SCHEMBL565693 | 0.85 | PROKR2 (0.61) | PROKR2EIF4EADORA2AADORA1 | |
| SCHEMBL13284632 | 0.85 | PROKR2 (0.41) | PROKR2 | |
| SCHEMBL565861 | 0.83 | PROKR2 (0.59) | PROKR2 | |
| SCHEMBL10107540 | 0.79 | PROKR2 (0.61) | PROKR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885MAPK1 1691/4885ANO1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.